SLC25A39: A key regulator of mitochondrial metabolism and a promising therapeutic target in cancer
- 1Department of Gynecology, Affiliated Hospital of Chengde Medical University, No. 36, Nanyingzi Street, Shuangqiao District, Chengde, 067000 Hebei China
- 2Department of Gynecology, The Second Clinical Medical College of Inner Mongolia Minzu University (Inner Mongolia Forestry General Hospital), Hulun Buir, 022150 Inner Mongolia China
- 3Department of Gynecology, Huadu District People’s Hospital of Guangzhou, No. 48, Xinhua Road, Huadu District, Guangzhou, 510800 Guangdong China
Abstract
The mitochondrial solute carrier (SLC25) family regulates solute transport across the mitochondrial inner membrane. Among them, SLC25A39 has emerged as a critical player in tumor biology, primarily through its dual role in mediating mitochondrial glutathione (mGSH) transport and maintaining iron-sulfur cluster homeostasis. Recent evidence implies that SLC25A39 dysfunction disrupts mGSH metabolism, thereby influencing iron-sulfur cluster synthesis and driving metabolic reprogramming in tumors. Notably, SLC25A39 is governed by a GSH-Fe-S-AFG3L2 feedback circuit, a feature not shared by its closest homolog SLC25A40. Additionally, upregulation of SLC25A39 is frequently observed in multiple malignancies, including colorectal, pancreatic, and liver cancers, where it correlates with enhanced proliferation, metastasis, and poor prognosis. Furthermore, SLC25A39 expression is intricately associated with remodeling of the tumor immune microenvironment and the development of therapeutic resistance, although these associations are primarily based on correlative evidence and require functional validation before causal conclusions can be drawn. This review synthesizes current knowledge on the molecular mechanisms by which SLC25A39 integrates mGSH transport with iron metabolism, and critically evaluates its emerging roles across different cancer types. We propose that beyond serving as a candidate prognostic biomarker, SLC25A39 represents a potential therapeutic target whose clinical utility remains to be established, and we discuss key unanswered questions regarding its tissue-specific functions and the translational challenges that lie ahead.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s12032-026-03466-5.
Related
- The Zα domain of ADAR1: emerging roles in cancer biology and evidence as a promising therapeutic target
- Fecal Microbiota Transplantation: A Promising Therapeutic Strategy Targeting the Microbiota-Gut-Brain Axis in Anorexia Nervosa.
- Thromboxane A2 receptor signalling amplifies osteoclastogenesis in rheumatoid arthritis through ACSL1 associated mitochondrial oxidative metabolism
- Enzymatic/Mitochondrial Import Bottleneck in Sepsis with Possible Extensions to DIC: IV Glutathione and Hinokitiol as Potential Therapeutic Candidates
- Terminal hydroxylation of eIF5A hypusination influences mitochondrial protein expression and cellular metabolism in fission yeast
BibTeX
@article{tian2026slc25a39,
title = {{SLC25A39: A key regulator of mitochondrial metabolism and a promising therapeutic target in cancer}},
author = {Tian Tian and Yan Jin and Penghua Cui and Suwei Lan},
journal = {Medical Oncology (Northwood, London, England)},
year = {2026},
month = oct,
doi = {10.1007/s12032-026-03466-5},
url = {https://doi.org/10.1007/s12032-026-03466-5},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - SLC25A39: A key regulator of mitochondrial metabolism and a promising therapeutic target in cancer
AU - Tian Tian
AU - Yan Jin
AU - Penghua Cui
AU - Suwei Lan
PY - 2026
DA - 2026/10/26
JO - Medical Oncology (Northwood, London, England)
DO - 10.1007/s12032-026-03466-5
UR - https://doi.org/10.1007/s12032-026-03466-5
AB - The mitochondrial solute carrier (SLC25) family regulates solute transport across the mitochondrial inner membrane. Among them, SLC25A39 has emerged as a critical player in tumor biology, primarily through its dual role in mediating mitochondrial glutathione (mGSH) transport and maintaining iron-sulfur cluster homeostasis. Recent evidence implies that SLC25A39 dysfunction disrupts mGSH metabolism, thereby influencing iron-sulfur cluster synthesis and driving metabolic reprogramming in tumors. Notably, SLC25A39 is governed by a GSH-Fe-S-AFG3L2 feedback circuit, a feature not shared by its closest homolog SLC25A40. Additionally, upregulation of SLC25A39 is frequently observed in multiple malignancies, including colorectal, pancreatic, and liver cancers, where it correlates with enhanced proliferation, metastasis, and poor prognosis. Furthermore, SLC25A39 expression is intricately associated with remodeling of the tumor immune microenvironment and the development of therapeutic resistance, although these associations are primarily based on correlative evidence and require functional validation before causal conclusions can be drawn. This review synthesizes current knowledge on the molecular mechanisms by which SLC25A39 integrates mGSH transport with iron metabolism, and critically evaluates its emerging roles across different cancer types. We propose that beyond serving as a candidate prognostic biomarker, SLC25A39 represents a potential therapeutic target whose clinical utility remains to be established, and we discuss key unanswered questions regarding its tissue-specific functions and the translational challenges that lie ahead. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s12032-026-03466-5.
SN - 1357-0560
SN - 1559-131X
ER -